Tiziana Life Sciences Ltd Cash Flow Conversion Efficiency

Latest as of March 2026: -115.846x

Tiziana Life Sciences Ltd cash flow conversion efficiency. Based on the latest financial reports, Tiziana Life Sciences Ltd (TLSA) has a cash flow conversion efficiency ratio of -115.846x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.02 Million) by net assets ($52.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Tiziana Life Sciences Ltd (1998–2025)

Cash flow conversion efficiency of Tiziana Life Sciences Ltd from 1998 to 2025. This chart illustrates how Tiziana Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View TLSA stock price for real-time trading data and today's change.

Tiziana Life Sciences Ltd Cash Flow Conversion Ratio Explained

Tiziana Life Sciences Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Tiziana Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tiziana Life Sciences Ltd ranked by their cash flow conversion efficiency. Also see how much is Tiziana Life Sciences Ltd worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Handok
KO:002390
0.001x
CTW Cayman Class A Ordinary Shares
NASDAQ:CTW
-0.041x
Eureka Acquisition Corp Unit
NASDAQ:EURKU
-0.006x
Oncopeptides AB
ST:ONCO
3.676x
Metrofile
JSE:MFL
0.237x
Nutriband Inc
NASDAQ:NTRB
-0.110x
Kukdong Oil &
KO:014530
0.071x
Xtract One Technologies Inc.
TO:XTRA
0.103x

Annual Cash Flow Conversion Efficiency for Tiziana Life Sciences Ltd (1998–2025)

The table below shows the annual cash flow conversion efficiency of Tiziana Life Sciences Ltd from 1998 to 2025. Review Tiziana Life Sciences Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $52.00K $-12.85 Million -247.058x -79644.98%
2024-12-31 $3.94 Million $-1.22 Million -0.310x +86.19%
2023-12-31 $5.54 Million $-12.42 Million -2.244x -174.65%
2022-12-31 $19.57 Million $-15.99 Million -0.817x -109.07%
2021-12-31 $41.28 Million $-16.13 Million -0.391x -178.41%
2020-12-31 $62.39 Million $-8.76 Million -0.140x -111.09%
2019-12-31 $-4.18 Million $-5.29 Million 1.266x +114.26%
2018-12-31 $409.01K $-3.63 Million -8.875x -362.93%
2017-12-31 $-1.68 Million $-5.68 Million 3.375x +299.20%
2016-12-31 $3.31 Million $-5.62 Million -1.694x -152.95%
2015-12-31 $8.50 Million $-5.70 Million -0.670x +48.54%
2014-12-31 $1.78 Million $-2.31 Million -1.302x -295.67%
2013-12-31 $-146.00K $-97.13K 0.665x -88.32%
2012-12-31 $-40.00K $-227.89K 5.697x +439.16%
2011-12-31 $525.00K $-881.91K -1.680x -148.77%
2010-12-31 $604.00K $-407.86K -0.675x -52.98%
2009-12-31 $1.21 Million $-535.42K -0.441x +38.37%
2008-12-31 $1.34 Million $-959.80K -0.716x +18.70%
2007-12-31 $2.44 Million $-2.15 Million -0.881x -8.97%
2006-12-31 $2.43 Million $-1.96 Million -0.809x -92.97%
2005-12-31 $2.83 Million $-1.18 Million -0.419x +13.69%
2004-12-31 $3.54 Million $-1.72 Million -0.485x +3.58%
2003-12-31 $3.03 Million $-1.52 Million -0.503x +29.33%
2002-12-31 $2.21 Million $-1.57 Million -0.712x +14.07%
2001-12-31 $2.96 Million $-2.46 Million -0.829x -51.50%
2000-12-31 $4.01 Million $-2.19 Million -0.547x -106.04%
1999-12-31 $1.98 Million $-527.00K -0.266x -93.05%
1998-12-31 $2.25 Million $-310.00K -0.138x --

About Tiziana Life Sciences Ltd

NASDAQ:TLSA USA Biotechnology
Market Cap
$72.52 Million
Market Cap Rank
#20361 Global
#4671 in USA
Share Price
$0.57
Change (1 day)
-6.65%
52-Week Range
$0.57 - $1.82
All Time High
$6.93
About

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more